Clinical Trial Update: A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma [Phase 3]

View source ↗

Summary

A Phase 3 trial to evaluate tezepelumab versus placebo in children aged 5 to under 12 with severe asthma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Tezepelumab (tezepelumab)

Snippet

Sponsor: AstraZeneca | Conditions: Asthma | Phase 3 | Status: RECRUITING